Motley Rice - Attorneys at Law
Navigation
Main navigation
Motley Rice represents clients across many areas.
Learn about the cases Motley Rice is actively representing clients in or cases that we've litigated previously.
People have filed lawsuits against weight loss drug manufacturers Novo Nordisk and Eli Lilly.
Lawsuits allege talcum powder use is linked to reproductive organ cancer for women.
Individuals who know of an FCA violation can file a qui tam whistleblower lawsuit.
Social media companies are being sued over alleged teenage mental health harms.
This library contains more than 2,000 exhibits cited in social media harm lawsuits across the United States.
Survivors of sexual abuse may hire a civil sexual abuse attorney to discuss what they’ve experienced and look into pursuing legal action.
Studies link hair relaxers to uterine/ovarian cancer. Lawsuits seek to hold companies accountable.
Asbestos-related diseases include mesothelioma, lung cancer and asbestosis.
ERISA sets minimum standards including which employees are eligible for benefits, how benefits must be calculated, and when benefits vest.
While litigation can take years to complete from start to finish, our firm is always working for our clients, no matter how long it takes or how hard it gets.
Motley Rice attorneys and support personnel are dedicated to representing clients and working with co-counsel located throughout the United States and around the world.
Comprehensive, up-to-date news on the issues surrounding the litigation areas of Motley Rice LLC.
Learn about the latest happenings from lawsuits and other events impacting plaintiffs, including the new Social Media Harm Evidence Library.
Read news coverage about Motley Rice, its clients and our efforts to hold defendants accountable.
Motley Rice lawyers share their insights on litigation and more to inform people exploring their legal options.
This case is no longer active
The Legal Team
A breach of fiduciary duty may occur when directors knowingly allow employees to engage in unlawful activities for the company’s own financial benefit. When the unlawful actions are discovered and penalized, shareholders can consider initiating a shareholder derivative action for the purpose of securing corporate governance reforms that are designed to prevent the reoccurrence of such misconduct.
On June 11, 2013, Walgreens announced that it had reached an $80 million settlement* with the Drug Enforcement Administration (DEA) – the largest in the agency’s history.
According to the DEA, Walgreens had committed an “unprecedented number” of record keeping and prescription dispensing violations and had exhibited a “staggering disregard” for its obligations as a DEA registrant by allowing opioids “to be diverted for abuse.” Following that announcement, a group of institutional investors filed a derivative complaint against members of the Walgreens board of directors seeking the implementation of a series of governance reforms.
Under the settlement, which was approved in December 2014, Walgreens agreed to extend certain compliance-related commitments—including maintaining a Department of Pharmaceutical Integrity composed of personnel with pharmacy-related training and managerial personnel who will coordinate compliance efforts related to controlled substances. The company also agreed to maintain periodic reporting of significant DEA-related matters to the Board’s Audit Committee, which in turn will periodically review its compliance program and its resources and receive quarterly reports from the company’s Chief Compliance Officer. Walgreens also agreed to ensure that all new company directors will receive, as part of their orientation program, information from Walgreens’ management regarding: (i) risk management issues facing the Company; and (ii) Walgreens’ compliance programs.
Motley Rice served as co-lead counsel in this case, working with our clients to achieve appropriate governance reforms.
The case is In re Walgreen Co. Derivative Litigation, No. 1:13-cv-05471 (N.D. Ill.).
If you have questions regarding cases similar to In re Walgreen Co. Derivative Litigation or if you would like to discuss a potential case, contact securities attorneys Gregg Levin or Bill Norton by email or at 1.800.768.4026.
*Prior results do not guarantee a similar outcome.